Search Results

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq, according to Guggenheim Partners analysts.

Nimble Therapeutics announced the formation of the Nimble Scientific Advisory Board to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.

Nimble Therapeutics today announced the opening of a second R&D site in Philadelphia, PA.

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific Officer (CSO).

Nimble Therapeutics announced that the company has expanded its collaboration and executed a license agreement with Genentech, a member of the Roche Group, for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas.

Nimble Therapeutics Inc., a leading peptide therapeutics company, announced they have achieved discovery milestones for two programs partnered with a large pharma company.

Visceral fat, also known as Visceral Adipose Tissue (VAT), is the adipose tissue inside the abdominal cavity. VAT is a central risk factor for Non-Alcoholic Fatty Liver Disease (NAFLD), liver cirrhosis, cardiovascular disease (CVD), and type-2 diabetes (T2D).